Journal ArticleDOI
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.
Reads0
Chats0
TLDR
In conclusion, romiplostim increased platelet counts in most patients for up to 156 weeks without tachyphylaxis and had an acceptable safety profile.About:
This article is published in Blood.The article was published on 2009-03-05. It has received 408 citations till now. The article focuses on the topics: Romiplostim & Thrombocytopenic purpura.read more
Citations
More filters
Journal ArticleDOI
International consensus report on the investigation and management of primary immune thrombocytopenia.
Drew Provan,Roberto Stasi,Adrian C. Newland,Victor S. Blanchette,Paula H. B. Bolton-Maggs,James B. Bussel,Beng H. Chong,Douglas B. Cines,Terry Gernsheimer,Bertrand Godeau,John D. Grainger,Ian A. Greer,Beverley J. Hunt,Paul Imbach,Gordon Lyons,Robert McMillan,Francesco Rodeghiero,Miguel A. Sanz,Michael D. Tarantino,Shirley Watson,Joan Young,David J. Kuter +21 more
TL;DR: This consensus document aims to report on new data and provide consensus-based recommendations relating to diagnosis and treatment of ITP in adults, in children, and during pregnancy.
Journal ArticleDOI
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.
TL;DR: This review identified the need for additional studies in many key areas of the therapy of ITP such as comparative studies of "front-line" therapy for ITP, the management of serious bleeding in patients withITP, and studies that will provide guidance about which therapy should be used as salvage therapy for patients after failure of a first-line intervention.
Journal ArticleDOI
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study
Gregory Cheng,Mansoor N. Saleh,Claus Werenberg Marcher,Sandra Y. Vasey,Bhabita Mayer,Manuel Aivado,Michael Arning,Nicole L. Stone,James B. Bussel +8 more
TL;DR: Eltrombopag is effective for management of chronic immune thrombocytopenia, and could be particularly beneficial for patients who have not responded to splenectomy or previous treatment, and should be balanced with the potential risks associated with eltrom bopag treatment.
Journal ArticleDOI
Romiplostim or standard of care in patients with immune thrombocytopenia.
David J. Kuter,Mathias J. Rummel,Ralph V. Boccia,B. Gail Macik,Ingrid Pabinger,Dominik Selleslag,Francesco Rodeghiero,Beng H. Chong,Xuena Wang,Dietmar Berger +9 more
TL;DR: Patients treated with romiplostim had a higher rate of a platelet response, lower incidence of treatment failure and splenectomy, less bleeding and fewer blood transfusions, and a higher quality of life than patients treated with the standard of care.
Journal ArticleDOI
New thrombopoietic growth factors
TL;DR: Two second-generation thrombopoietic growth factors stimulate growth of TPO-dependent cell lines via JAK2/STAT signaling pathways and increase platelet counts in animals and in healthy humans, TPO peptide and nonpeptide mimetics produced a dose-dependent rise in platelet count.
References
More filters
Journal ArticleDOI
High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood
Paul Imbach,V. d'APUZZO,Andreas Hirt,E. Rossi,M. Vest,Silvio Barandun,C. Baumgartner,Andreas Morell,Martin H. Schöni,H. P. Wagner +9 more
TL;DR: Seven children with chronic or intermittent ITP and six with acute idiopathic thrombocytopenic purpura were treated with large intravenous doses of polyvalent, intact immunoglobulin (Ig), and the platelet count rose sharply within 5 days, but the initial response and the subsequent course varied from patient to patient.
Journal ArticleDOI
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.
James N. George,Steven H. Woolf,Gary E. Raskob,Jeffrey S. Wasser,Louis M. Aledort,P. J. Ballem,Victor S. Blanchette,James B. Bussel,Douglas B. Cines,John G. Kelton,Alan E. Lichtin,Robert McMillan,JA Okerbloom,David H. Regan,Indira Warrier +14 more
TL;DR: This report begins with a brief summary of the panel’s recommendations, followed by a more detailed analysis of its methodology, the findings of the comprehensive literature review, and a full presentation of the recommendations.
Journal ArticleDOI
Immune thrombocytopenic purpura.
TL;DR: The authors of this up-to-date review discuss the current understanding of pathophysiology and, in particular, the way in which autoantibodies against platelets are generated.
Journal ArticleDOI
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
David J. Kuter,James B. Bussel,Roger M. Lyons,Vinod Pullarkat,Terry Gernsheimer,Francis M. Senecal,Louis M. Aledort,James N. George,Craig M. Kessler,Miguel A. Sanz,Howard A. Liebman,Frank T. Slovick,J. Th. M. de Wolf,Emmanuelle Bourgeois,Troy H. Guthrie,Adrian C. Newland,Jeffrey S. Wasser,Solomon I. Hamburg,Carlos Grande,François Lefrère,Alan E. Lichtin,Michael D. Tarantino,Howard R. Terebelo,Jean François Viallard,Francis J. Cuevas,Ronald S. Go,David H. Henry,Robert L. Redner,Lawrence Rice,Martin R. Schipperus,D. Matthew Guo,Janet L. Nichol +31 more
TL;DR: Romiplostim was well tolerated, and increased and maintained platelet counts in splenectomised and non-splenECTomised patients with ITP and treatment safety was good.
Journal Article
Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy
Drew Provan,Adrian C. Newland,D Norfolk,Paula H B Bolton-Maggs,J Lilleyman,Ian A. Greer,A May,Michael F. Murphy,Willem H. Ouwehand,Shirley Watson,Haematology Bcs. +10 more
TL;DR: This guideline aims to assess available diagnostic tests and therapies, and attempts to provide a rational approach to the diagnosis and treatment in adults, children and in pregnancy.
Related Papers (5)
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
David J. Kuter,James B. Bussel,Roger M. Lyons,Vinod Pullarkat,Terry Gernsheimer,Francis M. Senecal,Louis M. Aledort,James N. George,Craig M. Kessler,Miguel A. Sanz,Howard A. Liebman,Frank T. Slovick,J. Th. M. de Wolf,Emmanuelle Bourgeois,Troy H. Guthrie,Adrian C. Newland,Jeffrey S. Wasser,Solomon I. Hamburg,Carlos Grande,François Lefrère,Alan E. Lichtin,Michael D. Tarantino,Howard R. Terebelo,Jean François Viallard,Francis J. Cuevas,Ronald S. Go,David H. Henry,Robert L. Redner,Lawrence Rice,Martin R. Schipperus,D. Matthew Guo,Janet L. Nichol +31 more
International consensus report on the investigation and management of primary immune thrombocytopenia.
Drew Provan,Roberto Stasi,Adrian C. Newland,Victor S. Blanchette,Paula H. B. Bolton-Maggs,James B. Bussel,Beng H. Chong,Douglas B. Cines,Terry Gernsheimer,Bertrand Godeau,John D. Grainger,Ian A. Greer,Beverley J. Hunt,Paul Imbach,Gordon Lyons,Robert McMillan,Francesco Rodeghiero,Miguel A. Sanz,Michael D. Tarantino,Shirley Watson,Joan Young,David J. Kuter +21 more
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Francesco Rodeghiero,Roberto Stasi,Terry Gernsheimer,Marc Michel,Drew Provan,Donald M. Arnold,James B. Bussel,Douglas B. Cines,Beng H. Chong,Nichola Cooper,Bertrand Godeau,Klaus Lechner,Maria Gabriella Mazzucconi,Robert McMillan,Miguel A. Sanz,Paul Imbach,Victor S. Blanchette,Thomas Kühne,Marco Ruggeri,James N. George +19 more